Page 2 - Technology Incubation Program News Today

The Association of Public and Land-grant Universities (APLU) honors UConn’s success as economic engine and innovation driver for the state and region.

-- RLYB212 Phase 1b Proof-of-Concept Study Results Presented at the 31st Congress of the International Society of Thrombosis and Haemostasis in June 2023 -- -- RLYB212 Phase 1 Multiple Dose Cohort...

 -- RLYB212 Demonstrated Dose-Dependent, Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Mean Reduction in Platelet Elimination Half-Life After Subcutaneous Administration of RLYB212 was ≥90% in both RLYB212 Dose Groups, Achieving Proof-of-Concept Criteria -- -- Phase 2 Study in Pregnant Women at Higher Risk of HPA-1a Alloimmunization to be Initiated in 2H 2024 -- -- Phase 1 Multiple Dose Data and Maternal-Fetal Toxicology Data On-...

-- Data from the RLYB212 Phase 1b Proof-of-Concept Study to be Featured as an Oral Presentation at ISTH -- -- Company to Host Webcast Following ISTH Oral Presentation of RLYB212 --NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying a...

Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,... | June 1, 2023

-- RLYB212 Phase 1b Proof-of-Concept Study Results to be Presented at 31st Congress of the International Society of Thrombosis and Haemostasis in June 2023 -- -- Phase 1 Multiple Dose Cohort... | May 9, 2023

Rallybio Corporation , a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases,... | May 8, 2023

-- Data Support Potential Use of an Anti-HPA-1a Antibody as Prophylaxis for FNAIT -- -- In March 2023, Rallybio Announced Clinical Proof-of-Concept Achieved for its Lead Product Candidate, RLYB212, a... | April 6, 2023

YEREVAN, JANUARY 3, ARMENPRESS. TUMO Labs is running a 12-week Technology Incubation Program with a focus on EdTech, GreenTech and HealthTech.

Newly-minted UConn President Radenka Maric has ambitious goals and plans — related to climate change, business partnerships, research and fundraising — as she leads the state’s flagship university into 2023. Maric’s first full year as president follows a period of instability within UConn’s top ranks. Former President Thomas Katsouleas resigned suddenly from the post in the summer of 2021, after less than three years on the job. His interim replacement Andrew Agwunobi left the school a...